Want to see IN:GLAXO full AI Analyst Report?
GLAXO Stock Chart & Stats
₹2513.25
₹36.90(1.47%)
At close: 4:00 PM EDT
₹2513.25
₹36.90(1.47%)
Day’s Range― - ―
52-Week Range₹2,088.00 - ₹3,051.00
Previous CloseN/A
Volume67.92K
Average Volume (3M)1.83K
Market Cap
₹491.21B
Enterprise Value₹359.33K
Total Cash (Recent Filing)₹27.57B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)46.0
Beta0.69
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.96%
Share Statistics
EPS (TTM)63.05
Shares Outstanding169,406,040
10 Day Avg. Volume1,472
30 Day Avg. Volume1,831
Financial Highlights & Ratios
PEG Ratio3.20
Price to Book (P/B)17.06
Price to Sales (P/S)10.12
P/FCF Ratio39.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)69.03
Revenue Forecast (FY)₹42.43B
Bulls Say, Bears Say
Bulls Say
Improving Revenue And MarginsThe return to steady revenue growth, alongside materially improved net and EBIT margins, indicates stronger operating leverage or product mix. Sustaining these gains could support earnings growth and reinforce the company’s branded pharmaceutical position.
Minimal LeverageVery low debt reduces interest burden and refinancing risk, giving the company resilience during demand or pricing pressure. The conservative balance sheet also preserves capacity to fund products, manufacturing, distribution, or strategic initiatives.
Strong Free Cash Flow QualityClose conversion of earnings into free cash flow supports earnings quality and provides internally generated funding. Recent improvement in free cash flow strengthens the company’s ability to invest, maintain distributions, and absorb industry pressures.
Bears Say
Uneven Operating Cash ConversionVariable operating cash flow conversion suggests working-capital swings or collection and payment timing effects. Even with strong free cash flow overall, uneven cash realization can complicate planning and reduce the predictability of funding for operations.
Balance-Sheet VolatilityThe sharp reduction in equity and assets indicates that the balance sheet has not been uniformly stable despite minimal debt. Rebuilding is encouraging, but the historical movement warrants monitoring for exceptional items or changes in capital allocation.
Profitability VolatilityA non-recurring profitability spike makes historical earnings less representative and complicates forecasting. Investors must distinguish sustainable pharmaceutical operating margins from exceptional effects when assessing the durability of future earnings growth.
GlaxoSmithKline Pharmaceuticals Limited News
GLAXO FAQ
What was GlaxoSmithKline Pharmaceuticals Limited’s price range in the past 12 months?
GlaxoSmithKline Pharmaceuticals Limited lowest stock price was ₹2088.00 and its highest was ₹3051.00 in the past 12 months.
What is GlaxoSmithKline Pharmaceuticals Limited’s market cap?
GlaxoSmithKline Pharmaceuticals Limited’s market cap is ₹491.21B.
When is GlaxoSmithKline Pharmaceuticals Limited’s upcoming earnings report date?
GlaxoSmithKline Pharmaceuticals Limited’s upcoming earnings report date is Nov 05, 2026 which is in 74 days.
How were GlaxoSmithKline Pharmaceuticals Limited’s earnings last quarter?
GlaxoSmithKline Pharmaceuticals Limited released its earnings results on Aug 03, 2026. The company reported ₹14 earnings per share for the quarter, beating the consensus estimate of ₹13.9 by ₹0.1.
Is GlaxoSmithKline Pharmaceuticals Limited overvalued?
According to Wall Street analysts GlaxoSmithKline Pharmaceuticals Limited’s price is currently Overvalued.
Does GlaxoSmithKline Pharmaceuticals Limited pay dividends?
GlaxoSmithKline Pharmaceuticals Limited pays a Annually dividend of ₹57 which represents an annual dividend yield of 1.96%. See more information on GlaxoSmithKline Pharmaceuticals Limited dividends here
What is GlaxoSmithKline Pharmaceuticals Limited’s EPS estimate?
GlaxoSmithKline Pharmaceuticals Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does GlaxoSmithKline Pharmaceuticals Limited have?
GlaxoSmithKline Pharmaceuticals Limited has 169,406,040 shares outstanding.
What happened to GlaxoSmithKline Pharmaceuticals Limited’s price movement after its last earnings report?
GlaxoSmithKline Pharmaceuticals Limited reported an EPS of ₹14 in its last earnings report, beating expectations of ₹13.9. Following the earnings report the stock price went up 0.141%.
Which hedge fund is a major shareholder of GlaxoSmithKline Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in IN:GLAXO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Limited, an India-based healthcare enterprise, engages in the research, development, production, and global distribution of pharmaceutical drugs and vaccines. Its extensive product range encompasses both prescription and over-the-counter medications addressing diverse therapeutic areas such as anti-infectives, respiratory ailments, dermatology, nutritional deficiencies, gastrointestinal issues, and rare conditions. The company additionally provides consumer healthcare solutions. Prominent brands within its portfolio include Augmentin, Calpol, Ceftum, Eltroxin, Neosporin, Betnovate, Infanrix Hexa, Synflorix, and Boostrix, among numerous others. Founded in 1924 and headquartered in Mumbai, India, the company adopted its current name in 2001, having previously operated as SmithKline Beecham Pharmaceuticals India Ltd.
Technical Analysis
Abbott India Limited
―
Cipla Ltd
―
Gland Pharma Ltd.
―
PFIZER LIMITED
―
Sanofi Consumer Healthcare India Limited
―